KR890009415A - 항 비루스성 화합물 및 그 제조방법 - Google Patents
항 비루스성 화합물 및 그 제조방법 Download PDFInfo
- Publication number
- KR890009415A KR890009415A KR1019880017474A KR880017474A KR890009415A KR 890009415 A KR890009415 A KR 890009415A KR 1019880017474 A KR1019880017474 A KR 1019880017474A KR 880017474 A KR880017474 A KR 880017474A KR 890009415 A KR890009415 A KR 890009415A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- amino acid
- acid sequence
- hiv
- following amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 24
- 238000002360 preparation method Methods 0.000 title claims 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 7
- 241000725303 Human immunodeficiency virus Species 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010001513 AIDS related complex Diseases 0.000 claims 2
- 101710132601 Capsid protein Proteins 0.000 claims 2
- 101710094648 Coat protein Proteins 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 2
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 101710125418 Major capsid protein Proteins 0.000 claims 2
- 101710141454 Nucleoprotein Proteins 0.000 claims 2
- 101710083689 Probable capsid protein Proteins 0.000 claims 2
- 101710188315 Protein X Proteins 0.000 claims 2
- 102100021696 Syncytin-1 Human genes 0.000 claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 2
- 230000002378 acidificating effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 238000010647 peptide synthesis reaction Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (19)
- 인체 면역결핍증 비루스(HIV)입자와 외피 단백질 사이에 있는 접촉 영역중의 상기 입자의 외피 단백질 gp 41 및 gp120 사이의 상호작용을 방해 또는 저해할 수 있는 인체 면역결핍증 비루스(HIV)의 치료 또는 예방에 사용되는 화합물.
- 제 1 항에 있어서, 상기 HIV감염이 HIV1감염인 것을 특징으로 하는 화합물.
- 제 2 항에 있어서, 상기 외피 단백질 사이에서의 상호작용의 방해 또는 저해가 하기 아미노산 서열에 의해 정의되는 접촉 영역에 영향을 미치는 것을 특징으로 하는 화합물.
- 제 1 항에 있어서, 상기 HIV Ⅱ감염인 것을 특징으로 하는 화합물.
- 제 4 항에 있어서, 상기 외피 단백질 사이에서의 상호작용의 방해 또는 저해가 하기 아미노산 서열에 의해 정의되는 접촉영역에 영향을 미치는 것을 특징으로 하는 화합물.
- 제3항 또는 제5항에 있어서, 상기 아미노산 서열의 적어도 일부분이 gp 41또는 gp120 단백질인 것을 특징으로 하는 화합물.
- 제6항에 있어서, 하기 아미노산 서열 도는 그 일부분을 함유하는 화합물.H E D I I S L W D Q S L K P C V K T P L 또는 G I K Q L Q A R I L A V E R Y L K D Q Q
- 제7항에 있어서, 하기 아미노산 서열을 함유하는 화합물.H E D I I S L W D Q S L K
- 제1항에 있어서, 상기 접촉 영역에서 gp120 단백질의 산성 잔사와 상호 작용할수 있는 염기성 기능을 함유하는 화합물.
- 제1항에 있어서, 상기 접촉 영역에서 gp41의 접촉 영역의 염기성 잔사와 상호 작용할수 있는 산성기능을 함유하는 화합물.
- 제1항에 있어서, 상기 접촉 영역에서 gp41및/또는 gp120 단백질의 소수성 영역과 상호 작용할 수 있는 소수성 기능을 함유하는 화합물.
- 제1항에 있어서, 후천성 면역 결핍 증후군(AIDS)또는 AIDS관련 컴플렉스(ARC)의 치료 또는 예방에 사용되는 화합물.
- 제1항에 있어서, HIV-포지티브 개인의 치료 또는 예방에 사용되는 화합물.
- HIV감염의 치료 또는 예방용 약제 조제에 제1항에서 정의한 화합물을 사용하는 방법.
- 하기의 아미노산 서열 또는 그 일부분을 함유한든 팹티드 화합물.H E D I I S L W D Q S L K P C V K L T P L 또는 G I K Q L Q A R I L A V E R Y L K D Q Q
- 하기의 아미노산 서열을 가지는 펩티드 화합물.H E D I I S L W D Q S L K
- 제1항에서 정의한 화합물과 함께 적어도 하나의 약학적 허용담체 또는 부형제를 포함하는 약학제제.
- 제15항 또는 제16항에서 정의한 펩티드 화합물과 함께 적어도 하나의 약학적 허용 담체 또는 부형제를 포함하는 약학제제.
- 펩티드 합성 기술 분야내에서 공지된 공정을 포함하는 제15항 또는 16항에서 정의한 펩티드 화합물의 제조방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPI610187 | 1987-12-24 | ||
AUPI6101 | 1987-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR890009415A true KR890009415A (ko) | 1989-08-01 |
Family
ID=3772688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019880017474A KR890009415A (ko) | 1987-12-24 | 1988-12-24 | 항 비루스성 화합물 및 그 제조방법 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0323157A3 (ko) |
KR (1) | KR890009415A (ko) |
AU (1) | AU2757388A (ko) |
DK (1) | DK720588A (ko) |
HU (1) | HUT56855A (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5567805A (en) * | 1990-03-09 | 1996-10-22 | Administrators Of The Tulane Educational Fund | The cellular receptor for the CS3 peptide of human immunodeficiency virus |
AU7471991A (en) * | 1990-03-09 | 1991-10-10 | The Administrators Of The Tulane Eductional Fund | Peptide inhibitor of human immunodeficiency virus infection blocks virus interactions with a novel cellular receptor |
FR2677654B1 (fr) * | 1991-06-17 | 1995-11-17 | Pasteur Merieux Serums Vacc | Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv. |
NZ254640A (en) | 1992-07-20 | 1997-04-24 | Univ Duke | Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6017536A (en) * | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
US6140043A (en) * | 1995-08-18 | 2000-10-31 | Rentschler Biotechnologie Gmbh | Pharmaceutical compositions for competitively inhibiting the binding of a retrovirus to the IFN-receptor and means for diagnosis of an HIV infection |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2702911B2 (ja) * | 1985-09-11 | 1998-01-26 | ユナイテツド・バイオメデイカル・インコ−ポレ−テツド | 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法 |
GB8525615D0 (en) * | 1985-10-17 | 1985-11-20 | Hoffmann La Roche | Polypeptides |
AU7234387A (en) * | 1986-03-24 | 1987-10-20 | Ortho Pharmaceutical Corporation | Synthetic htlv-iii peptides, compositions and uses thereof |
-
1988
- 1988-12-22 EP EP88312216A patent/EP0323157A3/en not_active Withdrawn
- 1988-12-23 HU HU886582A patent/HUT56855A/hu unknown
- 1988-12-23 AU AU27573/88A patent/AU2757388A/en not_active Withdrawn
- 1988-12-23 DK DK720588A patent/DK720588A/da not_active Application Discontinuation
- 1988-12-24 KR KR1019880017474A patent/KR890009415A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2757388A (en) | 1989-06-29 |
DK720588A (da) | 1989-06-25 |
DK720588D0 (da) | 1988-12-23 |
HUT56855A (en) | 1991-10-28 |
EP0323157A3 (en) | 1990-07-25 |
EP0323157A2 (en) | 1989-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sarin et al. | Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone | |
Montagnier et al. | Identification and antigenicity of the major envelope glycoprotein of of lymphadenopathy-associated virus | |
ATE154610T1 (de) | Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung | |
CA2022539A1 (en) | Albumin derivatives with therapeutic functions | |
MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
EP0301570A3 (en) | Oligopeptides useful for treating aids | |
CA2073031A1 (en) | Anti-cd4 antibody homologs useful in prophylaxis and treatment of aids, arc and hiv infection | |
BR0008741A (pt) | Peptìdeo de hiv, antìgenos, composições de vacina, kit de imunoensaio e método de detecção de anticorpos induzidos por hiv | |
CO4750842A1 (es) | Pox virus recombinantes de mapache y vacuna eficaz contra la infeccion del virus de inmunodeficiencia felina . | |
DE69737736D1 (de) | Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) | |
HUP0202502A2 (hu) | Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására | |
EP0225066A3 (en) | Antigen determinant peptides and a process for the preparation thereof | |
KR890009415A (ko) | 항 비루스성 화합물 및 그 제조방법 | |
ATE135743T1 (de) | Monoklonale menschliche antikörper gegen hiv-i | |
KR930702509A (ko) | 사람 면역결핍 바이러스(hiv)면역치료제 | |
AU1226288A (en) | Processes for the preparation of medicinal compositions, compositions obtained by these processes and use thereof for the preparation of medicines against viral hepatitis b and acquired immunodeficiency syndrome | |
NZ220200A (en) | Hiv related peptides, antibodies to the peptides and vaccines therefrom | |
SE8701628D0 (sv) | Medel for analys mm | |
BR9508629A (pt) | Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica | |
ATE113210T1 (de) | Antivirale zusammensetzungen enthaltend sulfoquinovosylglycerolderivate und analoge davon. | |
KRUGNER-HIGBY et al. | Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/gp120 binding to monoclonal antibody | |
CA2057612A1 (en) | Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof | |
RU96116005A (ru) | Штамм hominis immunodeficiti virus (hiv-i) вич-i/россия/гм-12-95 (ru1295) субтипа в для диагностических и вакцинных препаратов | |
WO1993015730A1 (en) | Use of 5,5'-dithio-bis(2-nitrobenzoic acid) for inhibition of hiv protease | |
AU6393990A (en) | Hiv related peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |